Cao, Haoying’s team published research in Chemical Communications (Cambridge, United Kingdom) in 2022 | CAS: 1468-83-3

Chemical Communications (Cambridge, United Kingdom) published new progress about Coupling reaction catalysts. 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Category: benzothiophene.

Cao, Haoying published the artcileSynthesis of β-nitro ketones from geminal bromonitroalkanes and silyl enol ethers by visible light photoredox catalysis, Category: benzothiophene, the main research area is beta nitro ketone preparation; geminal bromonitroalkane silyl enol ether visible light photoredox catalysis.

Various β-nitro ketones, including those bearing a β-tertiary carbon, were prepared from geminal bromonitroalkanes and trimethylsilyl enol ethers of a broad range of ketones by visible light photoredox catalysis. Products which were then easily converted into β-amino ketones, 1,3-amino alcs., α,β-unsaturated ketones, β-cyano ketones and γ-nitro ketones.

Chemical Communications (Cambridge, United Kingdom) published new progress about Coupling reaction catalysts. 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Category: benzothiophene.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Beaune, P. H.’s team published research in European Journal of Haematology, Supplementum in 1996 | CAS: 40180-04-9

European Journal of Haematology, Supplementum published new progress about Drugs. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Related Products of benzothiophene.

Beaune, P. H. published the artcileAnti-cytochrome P450 autoantibodies in drug-induced disease, Related Products of benzothiophene, the main research area is review cytochrome P450 autoantibody drug.

A review with 23 references Drugs may induce hepatitis through immune mechanisms. In this review we have used the examples of 2 drugs to elucidate the first steps leading to the triggering of such disease, namely tienilic acid (TA) and dihydralazine (DH). These drugs are transformed into reactive metabolite(s) by cytochrome P 450 (2C9 for TA and 1A2 for DH) (step 1). The reactive metabolites produced are very short-lived and bind directly to the enzymes which generated them (step 2). A neoantigen is thus formed which triggers an immune response (step 3), characterized by the presence of autoantibodies in the patient’s serum (step 4). The autoantibodies are directed against the cytochrome P 450 which generated the metabolite(s). Although the process by which TA and DH induce hepatitis has been elucidated, further studies are necessary to generalize this mechanism. In addition, an animal model will also be useful to fully understand the immune mechanism of this type of disease.

European Journal of Haematology, Supplementum published new progress about Drugs. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Related Products of benzothiophene.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Thompson, Richard A.’s team published research in Chemical Research in Toxicology in 2012-08-20 | CAS: 40180-04-9

Chemical Research in Toxicology published new progress about Cytotoxicity. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.

Thompson, Richard A. published the artcileIn Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, the main research area is risk idiosyncratic adverse drug.

Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling. IADRs arise from both drug and patient related mechanisms and risk factors. Drug related risk factors, resulting from parent compound or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compound disposition, and/or immune activation. In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans. The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance associated protein 2, Mrp2. In addition, the CVB Burden was estimated by determining the CVB of radiolabeled compound to human hepatocytes and factoring in both the maximum prescribed daily dose and the fraction of metabolism leading to CVB. Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.

Chemical Research in Toxicology published new progress about Cytotoxicity. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Williams, Dominic P.’s team published research in Chemical Research in Toxicology in 2020-01-21 | CAS: 40180-04-9

Chemical Research in Toxicology published new progress about Biotransformation. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Related Products of benzothiophene.

Williams, Dominic P. published the artcilePredicting Drug-Induced Liver Injury with Bayesian Machine Learning, Related Products of benzothiophene, the main research area is machine learning drug liver toxicity prediction risk assessment.

Drug induced liver injury (DILI) can require significant risk management in drug development, and on occasion can cause morbidity or mortality, leading to drug attrition. Optimizing candidates preclinically can minimise hepatotoxicity risk but it is difficult to predict due to multiple etiologies encompassing DILI, often with multifactorial and overlapping mechanisms. In addition to epidemiol. risk factors, physicochem. properties, dose, disposition, lipophilicity, and hepatic metabolic function are also relevant for DILI risk. Better human relevant, predictive models are required to improve hepatotoxicity risk assessment in drug discovery. The authors’ hypothesis is that integrating mechanistically relevant hepatic safety assays with Bayesian machine learning will improve hepatic safety risk prediction. The authors present a quant. and mechanistic risk assessment for candidate nomination using data from in vitro assays (hepatic spheroids, BSEP, mitochondrial toxicity and bioactivation), together with physicochem. (cLogP) and exposure (Cmaxtotal) variables from a chem. diverse compound set (33 no/low-, 40 medium- and 23 high-severity DILI compounds). The Bayesian model predicts the continuous underlying DILI severity and uses a data-driven prior distribution over the parameters to prevent overfitting. The model quantifies the probability that a compound falls into either no/low, medium, or high-severity categories, with a balanced accuracy of 63% on held-out samples, and a continuous prediction of DILI severity along with uncertainty in the prediction. For a binary yes/no DILI prediction, the model has a balanced accuracy of 86%, a sensitivity of 87%, a specificity of 85%, a pos. predictive value of 92%, and a neg. predictive value of 78%. Combining physiol. relevant assays, improved alignment with FDA recommendations, and optimal statistical integration of assay data, leads to improved DILI risk prediction.

Chemical Research in Toxicology published new progress about Biotransformation. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Related Products of benzothiophene.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Stepan, Antonia F.’s team published research in Chemical Research in Toxicology in 2011-09-19 | CAS: 40180-04-9

Chemical Research in Toxicology published new progress about Biological detoxification. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Category: benzothiophene.

Stepan, Antonia F. published the artcileStructural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States, Category: benzothiophene, the main research area is review reactive metabolite medicinal chem drug toxicity.

Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examined as part of lead optimization efforts in drug discovery. Likewise, avoidance of “”structural alerts”” is almost a norm in drug design. However, there is a growing concern that the perceived safety hazards associated with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated. In addition, the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities. Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern. Could the mol. in its parent form exert toxicity. Can a low dose drug candidate truly mitigate metabolism-dependent and -independent idiosyncratic toxicity risks. In an effort to address these questions, we have retrospectively examined 68 drugs (recalled or associated with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs. Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs associated with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols. In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors. Most drugs were administered at daily doses exceeding several hundred milligrams. There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. weight, lipophilicity, etc. Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos. Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category. However, with relatively few exceptions, the vast majority of these drugs are rarely associated with idiosyncratic toxicity, despite years of patient use. The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses. In addition, competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category. Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery. Thus, in addition to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compound(s)) for lead compounds, effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compound liabilities. However, the prospective use of such data in compound selection will require further validation of the cellular assays using marketed agents. Until we gain a better understanding of the pathophysiol. mechanisms associated with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the associated “”body burden”” of the parent drug and its metabolites will remain an overarching goal in drug discovery.

Chemical Research in Toxicology published new progress about Biological detoxification. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Category: benzothiophene.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Agatonovic-Kustrin, Snezana’s team published research in Combinatorial Chemistry & High Throughput Screening in 2014-12-31 | CAS: 40180-04-9

Combinatorial Chemistry & High Throughput Screening published new progress about Analgesics. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Formula: C13H8Cl2O4S.

Agatonovic-Kustrin, Snezana published the artcileMolecular Structural Characteristics Important in Drug-HSA Binding, Formula: C13H8Cl2O4S, the main research area is acecainide analgesics antibiotic anticancer protein binding structure activity relationship.

A non-linear quant. structure activity relationship (QSAR) model based on 350 drug mols. was developed as a predictive tool for drug protein binding, by correlating exptl. measured protein binding values with ten calculated mol. descriptors using a radial basis function (RBF) neural network. The developed model has a statistically significant overall correlation value (r > 0.73), a high efficiency ratio (0.986), and a good predictive squared correlation coefficient (q2) of 0.532, which is regarded as producing a robust and high quality QSAR model. The developed model may be used for the screening of drug candidate mols. that have high protein binding data, filtering out compounds that are unlikely to be protein bound, and may assist in the dose adjustment for drugs that are highly protein bound. The advantage of using such a model is that the percentage of a potential drug candidate that is protein bound (PB (%)) can be simply predicted from its mol. structure.

Combinatorial Chemistry & High Throughput Screening published new progress about Analgesics. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Formula: C13H8Cl2O4S.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Zhang, Hao’s team published research in Organic Letters in 2020-09-18 | CAS: 1468-83-3

Organic Letters published new progress about Cyanamides Role: SPN (Synthetic Preparation), PREP (Preparation). 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Formula: C6H6OS.

Zhang, Hao published the artcileAccess to Cyanoimines Enabled by Dual Photoredox/Copper-Catalyzed Cyanation of O-Acyl Oximes, Formula: C6H6OS, the main research area is oxime acyl trimethylsilyl cyanide copper iridium light photoredox cyanation; cyanoimine preparation; hydroxamide acyl trimethylsilyl cyanide copper iridium light photoredox cyanation; cyanoamide preparation.

An efficient strategy for the synthesis of pharmaceutically important and synthetically useful cyanoimines, as well as cyanamides, has been described. This strategy is enabled by dual photoredox/copper-catalyzed cyanation of O-acyl oximes or O-acyl hydroxamides. This state of the art protocol for cyanoimines and cyanamides features readily available starting materials, mild reaction conditions, good functional group tolerance, and operational simplicity. The resultant cyanoimines can be transformed into structurally diverse and functionally important N-containing heterocycles.

Organic Letters published new progress about Cyanamides Role: SPN (Synthetic Preparation), PREP (Preparation). 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Formula: C6H6OS.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Guan, Ting’s team published research in Green Chemistry in 2022 | CAS: 1468-83-3

Green Chemistry published new progress about Bond cleavage catalysts. 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Computed Properties of 1468-83-3.

Guan, Ting published the artcilePhotoredox-catalyzed regio- & stereoselective C(sp2)-H cyanoalkylation of enamides with cycloketone oximes via selective C-C bond cleavage/radical addition cascade, Computed Properties of 1468-83-3, the main research area is cyanoalkyl enamide preparation regioselective diastereoselective green chem; enamide cycloketone oxime Heck type cyanoalkylation photoredox catalyst.

A photoredox-catalyzed regio- and stereoselective Heck-type cyanoalkylation of synthetically prominent enamides R1C(=CH2)N(R2)(R3) (R1 = Ph, thiophen-3-yl, 2H-1,3-benzodioxol-5-yl, etc.; R2 = Ac, Bn; R3 = Bn, Me, cyclohexylmethyl, etc.) with cycloketone oximes I (Y = CH, N; R4 = H, n-C6H13, cyclohexylmethyl, Bn, etc.; R5 = H, Ph, CN, Boc, etc.; n = 1, 2) via selective β-C-C bond scission/selective radical addition cascade is developed, enabling the incorporation of synthetically versatile and pharmaceutically appealing distal cyanoalkyl moieties into enamide scaffolds R1C(N(R2)(R3))=CHCH(R4)Y(R5)(CH2)nCN under mild conditions. The synthetic importance of this methodol. was highlighted by the broad substrate scopes, satisfying functional group compatibilities, excellent regio- and stereoselectivities as well as the versatile and diverse synthetic applications of β-cyanoalkylated enamides.

Green Chemistry published new progress about Bond cleavage catalysts. 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Computed Properties of 1468-83-3.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Shah, Falgun’s team published research in Toxicological Sciences in 2015-10-31 | CAS: 40180-04-9

Toxicological Sciences published new progress about Drug discovery. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.

Shah, Falgun published the artcileSetting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, the main research area is drug induced liver injury assay hepatotoxicity BSEP mitochondria inhibition; Liver Toxicity Knowledge Base; drug-induced liver injury; plasma exposure; safety margin.

Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms. Numerous exptl. approaches have been published to improve human DILI prediction with modest success. A retrospective anal. of 125 drugs (70 = most-DILI, 55 = no-DILI) from the Food and Drug Administration Liver Toxicity Knowledge Base was used to investigate DILI prediction based on consideration of human exposure alone or in combination with mechanistic assays of hepatotoxic liabilities (cytotoxicity, bile salt export pump inhibition, or mitochondrial inhibition/uncoupling). Using this dataset, human plasma Cmax,total ≥ 1.1 μM alone distinguished most-DILI from no-DILI compounds with high sensitivity/specificity (80/73%). Accounting for human exposure improved the sensitivity/specificity for each assay and helped to derive predictive safety margins. Compounds with plasma Cmax,total ≥ 1.1 μM and triple liabilities had significantly higher odds ratio for DILI than those with single/dual liabilities. Using this approach, a subset of recent pharmaceuticals with evidence of liver injury during clin. development was recognized as potential hepatotoxicants. In summary, plasma Cmax,total ≥ 1.1 μM along with multiple mechanistic liabilities is a major driver for predictions of human DILI potential. In applying this approach during drug development the challenge will be generating accurate estimates of plasma Cmax, total at efficacious doses in advance of generating true exposure data from clin. studies. In the meantime, drug candidates with multiple hepatotoxic liabilities should be deprioritized, since they have the highest likelihood of causing DILI in case their efficacious plasma Cmax,total in humans is higher than anticipated.

Toxicological Sciences published new progress about Drug discovery. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

 

Cui, Jianguo’s team published research in Tetrahedron in 2020-03-06 | CAS: 1468-83-3

Tetrahedron published new progress about Keto esters Role: RCT (Reactant), SPN (Synthetic Preparation), RACT (Reactant or Reagent), PREP (Preparation). 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Application In Synthesis of 1468-83-3.

Cui, Jianguo published the artcileOxidative umpolung selenocyanation of ketones and arenes: An efficient protocol to the synthesis of selenocyanates, Application In Synthesis of 1468-83-3, the main research area is ketone potassium selenocyanate oxidative umpolung selenocyanation; keto ester potassium selenocyanate oxidative umpolung selenocyanation; arene potassium selenocyanate regioselective oxidative umpolung selenocyanation.

A practical method for the umpolung selenocyanation of aryl ketones, alkyl ketones, β-ketoesters and electron-rich arenes was developed, afforded various selenocyanates in moderate to excellent yields. This transformation proceeded by an oxidative umpolung selenocyanation through nitrogen oxides-mediated electrophilic selenocyanation process. This method is simpler, more efficient, and less costly than precedent methods. Further transformations of the arylselenocyanate was performed to prove the synthetic utility of this methodol.

Tetrahedron published new progress about Keto esters Role: RCT (Reactant), SPN (Synthetic Preparation), RACT (Reactant or Reagent), PREP (Preparation). 1468-83-3 belongs to class benzothiophene, name is 3-Acetylthiophene, and the molecular formula is C6H6OS, Application In Synthesis of 1468-83-3.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem